IRCT20140818018842N51 IRCT 2025-12-12 Tehran University of Medical Sciences Does Eltrombopag Improve Blood Cell Recovery in Leukemia Patients After Transplant? Efficacy of Prophylactic Oral Eltrombopag for Promoting Platelet and Neutrophil Engraftment After Haploidentical Hematopoietic Stem Cell Transplantation in Patients with acute lymphoblastic leukemia: A Phase II Non Randomized-controlled Trial 2025-10-23 anticipated 30 Recruiting https://irct.ir/trial/82982 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Acute lymphoblastic leukemia [ALL]. Intervention 1: Intervention group: Patient with acute leukemia and recipient of haploidentical transplant will receive oral Eltrombopag, which is a thrombopoietin receptor agonist and will be used to promote post- allogenic-hematopoietic-stem-cell-transplantation engraftment, at a daily dose of 150–300 mg starting from fifth day after transplantation and continuing daily until engraftment. Each patient will receive Eltrombopag for a minimum of 10 days, regardless of whether engraftment occurs before day 10 of Eltrombopag therapy. Patients must receive at least 10 consecutive days of Eltrombopag in order to be included in the final analysis. As a safety rule, if the patient’s platelet count reaches or exceeds 500,000 per μL after 10 days, at any point during treatment, Eltrombopag must be discontinued. The eltrombopag used in this study will be purchased from Nano Darou Pharmaceutical Company. Intervention 2: Historical control patients will include patients with acute leukemia who received a haploidentical transplant and did not receive any medication to promote engraftment. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information available.